In the drug core target PPI network, EGFR, FOS, and MMP9 occupy pivotal positions and are also core targets involved in AD signaling pathways, indicating that these targets may be the main targets of MFXD in treating AD and play key roles in its therapeutic effects. This evidence concerns the gene MMP9 and Alzheimer disease.